Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:32 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer
NCT02612194 · Wake Forest University Health Sciences · PHASE2 · terminated · last registry update 2022-11-03 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Study closed to accrual due to low accrual numbers.” | – | Registry record, Wake Forest University Health Sciences |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against MET within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-10-30Results posted on the registry: Novartis Pharmaceuticals, Capmatinib + Osimertinib (NCT04816214)
- 2023-10-30Also stopped (terminated): Aravive, Inc., Batiraxcept + Cabozantinib (Cabo) (NCT04300140)
- 2023-10-23Phase 3 first posted: AbbVie, Telisotuzumab Vedotin + Osimertinib (NCT06093503)
- 2023-10-18Also stopped (terminated): Criterium, Inc., Tepotinib (NCT04739358)
- 2023-10-17Results posted on the registry: University of Colorado, Denver, Cabozantinib + Pembrolizumab (NCT03149822)
- 2023-10-17Also stopped (terminated): National Cancer Institute (NCI), Savolitinib (NCT03592641)
- 2023-10-13Phase 3 first posted: Shenzhen TargetRx Co., Ltd., TGRX-326 + Crizotinib (NCT06082635)
- 2023-10-13Also stopped (terminated): Istituto Oncologico Veneto IRCCS, ARQ197 (NCT02608411)
- 2023-10-10Results posted on the registry: Merck KGaA, Darmstadt, Germany, Tepotinib TF2 + Tepotinib TF3 (NCT03629223)
- 2023-09-21Also stopped (terminated): Fate Therapeutics, FT536 + Cyclophosphamide (NCT05395052)
- 2023-09-15Results posted on the registry: SCRI Development Innovations, LLC, Afatinib + Regorafenib (NCT02795156)
- 2023-09-08Also stopped (terminated): University of Nebraska, Cabozantinib (NCT03201250)
- 2023-08-14Phase 3 first posted: IDEAYA Biosciences, IDE196 + Crizotinib (NCT05987332)
- 2023-08-08Results posted on the registry: National Cancer Institute (NCI), Savolitinib (NCT03592641)
- 2023-08-07Results posted on the registry: Merck KGaA, Darmstadt, Germany, Dabigatran Etexilate + Tepotinib (NCT03492437)
- 2023-07-28Results posted on the registry: Merck KGaA, Darmstadt, Germany, Tepotinib + Omeprazole (NCT03531762)
- 2023-07-28Results posted on the registry: Merck KGaA, Darmstadt, Germany, Midazolam + Tepotinib (NCT03628339)
- 2023-07-20Results posted on the registry: Dana-Farber Cancer Institute, Cabozantinib (NCT01466036)
- 2023-07-07Also stopped (terminated): Pfizer, Avelumab + PF-06463922 (NCT02584634)
- 2023-07-03Results posted on the registry: Novartis Pharmaceuticals, Spartalizumab + Capmatinib (NCT02795429)
- 2023-06-18Results posted on the registry: Novartis Pharmaceuticals, Capmatinib + Nazartinib (NCT02335944)
- 2023-06-18Also stopped (terminated): Novartis Pharmaceuticals, Capmatinib + Nazartinib (NCT02335944)
- 2023-06-09Results posted on the registry: EMD Serono Research & Development Institute, Inc., Tepotinib (NCT02864992)
- 2023-05-24Results posted on the registry: University of Alabama at Birmingham, Cabozantinib (NCT02101736)
- 2023-05-18Results posted on the registry: Exelixis, Cabozantinib + Placebo (NCT03690388)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision